39947-04-1

Basic information

• Product Name: N6-Benzoyl-2',3'-isopropylideneadenosine
• Synonyms: N6-Benzoyl-2',3'-isopropylideneadenosine;N6-Benzoyl-2',3'-O-isopropylideneadenosine
• CAS NO: 39947-04-1
• Molecular Formula: C₂₀H₂₁N₅O₅
• Molecular Weight: 411.42
• Mol File: 39947-04-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 144-146 °C
• Appearance: /
• Density: 1.58±0.1 g/cm3(Predicted)
• PKA: 14.14±0.10(Predicted)
• CAS DataBase Reference: N6-Benzoyl-2',3'-isopropylideneadenosine(CAS DataBase Reference)
• NIST Chemistry Reference: N6-Benzoyl-2',3'-isopropylideneadenosine(39947-04-1)
• EPA Substance Registry System: N6-Benzoyl-2',3'-isopropylideneadenosine(39947-04-1)

Safety Data

• Hazardous Substances Data: 39947-04-1(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 4546-55-8 N-benzoyladenosine 
• 67-64-1 acetone 
• 1348775-39-2 adenosine 
• 245544-64-3 2',3'-O-isopropylidene-5'-O-(trimethylsilyl)adenosine 
• 58-61-7 adenosine 
• 77-76-9 2,2-dimethoxy-propane 
• 362-75-4 2',3'-isopropylidene adenosine 
• 93135-69-4 N⁶,5'-O-dibenzoyl-2',3'-O-isopropylideneadenosine 
• 39947-05-2 ((3aR,4R,6R,6aR)-6-(6-benzamido-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate 
• 114743-94-1 N⁶-benzoyl-7,8-dihydro-2',3'-O-isopropylideneadenosine 
• 93135-62-7 2',3'-O-isopropylidene-N⁶,N⁶,5'-O-tribenzoyladenosine 

Downstream Products

• 155264-06-5 Diisopropyl-phosphoramidous acid (3aR,4R,6R,6aR)-6-(6-benzoylamino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester methyl ester 
• 119750-97-9 N⁶-benzoyl-2',3'-isopropylidene-5'-carboxylic acid-5'-deoxy-adenosine 
• 1005190-81-7 N⁶-benzoyl-2′,3′-O-isopropylidene-5′-O-propargyladenosine 
• 43077-06-1 6-N-benzoyl-2',3'-O-isopropylideneadenosine-5'-aldehyde 
• 81921-52-0 (5'S)-N⁶-benzoyl-8,5'-cyclo-2',3'-O-isopropylideneadenosine 
• 34245-48-2 5'-azido-5'-deoxy-2',3'-O-isopropylidene adenosine 
• 21950-36-7 5'-amino-5'-deoxy-2',3'-O-isopropylideneadenosine 
• 674791-57-2 N-{9-[6-(1-hydroxy-pentyl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-9H-purin-6-yl}-benzamide 
• 43077-04-9 6-N-benzoyl-9-(2,3-O-isopropylidene-β-D-ribo-pentodialdo-1,5-furanosyl)adeninehydrate 
• 68224-54-4 N-(9-((3aR,4R,6R,6aR)-6-((S)-1-hydroxyethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide 
• 582295-71-4 C₆₄H₇₇N₇O₁₄Si 
• 582295-69-0 N-[8-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-9-(2,2-dimethyl-6-triisopropylsilanyloxymethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl]-benzamide 
• 582295-70-3 N-[8-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-9-(6-hydroxymethyl-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl]-benzamide 
• 582295-68-9 N⁶-benzoyl-8-(hydroxymethyl)-2',3'-O-isopropylidene-5'-O-(triisopropylsilyl)adenosine 

Relevant articles and documents

DERIVATIVES OF GLYCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE

The disclosure provides compounds, compositions and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen. The disclosure also provides heterocyclic compounds of formula (I) as agonists of alpha protein kinase 1 (ALPK1) and their use in activating ALPK1, modulating an immune response and treating diseases such as cancer, wherein A1, A2, L1, L2, L3, Z1, Z2, W1, W2, R1, R2, R3, R4, R5, R6 and R7 are as defined herein.

PROTEIN ARGININE N-METHYLTRANSFERASES INHIBITORS AND USES THEREOF

The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use thereof as a drug, notably in the treatment of cancer, or as a PRMT inhibitor. The present invention relates also to a pharmaceutical composition containing such a compound and to a method for the preparation of such a compound.

CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE

Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.